Valuation : Dimerix Limited

Market Cap 150M 108M 92.75M 87.82M 79.6M 149M 10.28B 1.04B 401M 5.23B 404M 395M 16.53B P/E 2025
-24.3x
P/E 2026 -4.13x
Enterprise Value 134M 96.23M 82.91M 78.51M 71.16M 134M 9.19B 932M 359M 4.68B 361M 353M 14.78B EV / Sales 2025
49.4x
EV / Sales 2026 16.9x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 week-12.28%
Current month-10.71%
1 month-12.28%
3 months+47.06%
6 months-30.56%
Current year-54.55%
1 week 0.24
Extreme 0.245
0.29
1 month 0.24
Extreme 0.245
0.33
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 27/08/2018
Director of Finance/CFO 59 29/01/2026
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 61 03/07/2015
Chairman - -
Director/Board Member - 27/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-12.28%-46.81%+309.84% 108M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average +0.44%-4.44%+49.00%+127.00% 26.49B
Weighted average by Cap. +0.41%-3.67%+73.11%+123.65%

Financials

2025 2026
Net sales 5.59M 4.01M 3.45M 3.27M 2.96M 5.56M 383M 38.82M 14.93M 195M 15.05M 14.72M 615M 6.35M 4.56M 3.93M 3.72M 3.37M 6.32M 435M 44.16M 16.98M 221M 17.11M 16.74M 700M
Net income -13.25M -9.5M -8.19M -7.75M -7.03M -13.18M -908M -92.09M -35.41M -462M -35.69M -34.91M -1.46B -29.81M -21.38M -18.42M -17.44M -15.81M -29.66M -2.04B -207M -79.67M -1.04B -80.3M -78.54M -3.28B
Net Debt -68.19M -48.9M -42.14M -39.9M -36.16M -67.84M -4.67B -474M -182M -2.38B -184M -180M -7.51B -15.92M -11.42M -9.84M -9.32M -8.44M -15.84M -1.09B -111M -42.55M -555M -42.89M -41.94M -1.75B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
11/09/26 A$0.2500 0.00% 810,805
10/09/26 A$0.2500 -3.85% 1,392,741
09/09/26 A$0.2600 -3.70% 1,125,101
08/09/26 A$0.2700 -3.57% 815,693
07/09/26 A$0.2800 -1.75% 899,948
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!